Difference between revisions of "Paliperidone LA-Amisulpride"
From Psychiatrienet
(Created page with '{{NAY}}') |
|||
| Line 1: | Line 1: | ||
{{NAY}} | {{NAY}} | ||
| + | {{switch-to-(9OH-)risperidone}} | ||
Revision as of 10:29, 6 May 2011
Paliperidone palmitate is since spring 2011 approved by EMEA: therefore this switch is under construction.
There are 2 switch possibities:
Number 1 (the general approach):
- Day 1: Switch to oral risperidone (or oral paliperidone): see this switch in the main cross table.
- Day 1-29: Maintain on oral risperidone (or oral paliperidone) and examine the effects.
- Day 30: stop oral risperidone (or oral paliperidone) and administer paliperidone-LA: see this switch in the main cross table.
Oral risperidone has better and more stable bioavailability properties than has oral 9-OH-risperidone=paliperidone. Food increases the absorption with 50-60% of the latter.
Number 2 (if a patient in the past reacted well on risperidon or paliperidone=9-OH-risperidone):
